GE HealthCare
GEHC
$59.48
-13.16%
GE HealthCare Technologies Inc. is a leading global medical technology company operating in the healthcare sector, with a core business focused on manufacturing and servicing imaging and ultrasound equipment, advanced visualization solutions, patient care systems, and pharmaceutical diagnostics. The company is a distinct market leader in medical imaging, leveraging its heritage from General Electric to maintain a strong competitive position through a diversified portfolio and a significant recurring revenue stream from services and consumables. The current investor narrative centers on the company's performance as a standalone entity post-spin-off, with attention on its ability to navigate a challenging demand environment, as evidenced by recent quarterly revenue declines, while simultaneously executing its strategy to drive growth through innovation and operational efficiency.…
GEHC
GE HealthCare
$59.48
Related headlines
Investment Opinion: Should I buy GEHC Today?
Rating: Hold. The core thesis is that GEHC is a fundamentally sound company with a strong market position caught in a cyclical downturn, but the timing of a recovery is too uncertain to warrant a Buy rating, given the severe recent underperformance.
Supporting evidence includes a reasonable forward P/E of 12.38x, which prices in a recovery, and robust TTM free cash flow of $1.506 billion that provides operational resilience. However, these positives are counterbalanced by the severe -12.13% YoY revenue decline and the stock's persistent technical downtrend, having underperformed the S&P 500 by -27.98% over the past year. Analyst sentiment is mixed but generally cautious, reflecting this uncertainty.
The thesis would upgrade to a Buy if quarterly revenue growth turns positive and gross margins stabilize above 40%, signaling the downturn has bottomed. It would downgrade to a Sell if revenue decline accelerates further below -15% YoY or if the stock breaks decisively below the $66.95 support level on high volume. Currently, the stock appears fairly valued relative to its depressed near-term prospects but undervalued if a 2026 recovery materializes as implied by the forward P/E.
Sign up to view all
GEHC 12-Month Price Forecast
The assessment is neutral with medium confidence. The company's strong cash generation and reasonable forward valuation create a potential value opportunity, but this is entirely contingent on arresting the severe top-line decline. The stock is in a clear downtrend with weak momentum, suggesting the market is pricing in continued pain. The stance would upgrade to bullish on concrete evidence of revenue stabilization (e.g., two consecutive quarters of flat or positive sequential growth). It would turn bearish if the stock breaks below the $66.95 support on worsening fundamentals.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on GE HealthCare's 12-month outlook, with a consensus price target around $77.33 and implied upside of +30.0% versus the current price.
Average Target
$77.33
12 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
12
covering this stock
Price Range
$48 - $77
Analyst target range
A cohort of 12 analysts provides coverage, with recent institutional ratings showing a mix of Buy, Overweight, and Equal Weight/Neutral stances, indicating a generally constructive but cautious consensus view. The average revenue estimate for the coming period is $25.49 billion, with a tight range from $24.95 billion to $25.90 billion, signaling strong analyst conviction in the near-term revenue outlook, while the wide dispersion between the high and low stock price targets would typically reflect differing assumptions on margin recovery and growth normalization, though specific target prices are not provided in the data to calculate implied upside.
Bulls vs Bears: GEHC Investment Factors
The bearish evidence currently outweighs the bullish case, driven by the severe and accelerating deterioration in fundamental performance. The most important tension in the investment debate is whether the company's strong free cash flow and reasonable valuation can provide a floor while it navigates a cyclical downturn, or if the revenue and earnings declines are indicative of a more structural problem that will lead to further multiple compression. The resolution of this tension hinges on the next few quarters' revenue trends and margin stability.
Bullish
- Strong Free Cash Flow & Liquidity: The company generates robust free cash flow of $1.506 billion TTM, providing a solid financial cushion. This cash generation, coupled with a current ratio of 1.18, gives GEHC significant flexibility to navigate the current downturn, invest in innovation, and return capital to shareholders.
- Attractive Forward Valuation: The forward P/E of 12.38x is significantly lower than the trailing P/E of 17.97x, reflecting market expectations for an earnings recovery. This valuation is reasonable for a healthcare technology leader and is below the stock's own historical highs, suggesting limited downside from a multiple perspective.
- Recurring Revenue Base: Approximately 50% of revenue is recurring from services, diagnostics, and digital solutions. This provides a stable financial foundation, mitigating some of the cyclicality in equipment sales and supporting cash flow generation during periods of weak demand.
- Analyst Conviction on Revenue Outlook: Analyst revenue estimates for the coming period show a tight range ($24.95B to $25.90B) around an average of $25.49B. This high level of consensus indicates strong conviction in the company's near-term revenue trajectory, despite recent quarterly declines.
Bearish
- Severe Revenue Contraction: Q4 2025 revenue declined -12.13% YoY to $4.674B, and sequentially from $5.143B in Q3. This accelerating top-line contraction is the most critical bearish signal, indicating a challenging demand environment that pressures the core investment thesis.
- Sharp Profitability Deterioration: Net income plummeted to $184M in Q4 2025 from $720M a year ago, representing severe margin compression. The TTM net margin of 10.1% is under pressure, and the sequential decline in quarterly gross margin from 54.3% in Q4 to lower levels in prior quarters adds to concerns.
- Pronounced Technical Downtrend: The stock is down 13.71% over 3 months and trades at just 23.3% of its 52-week range, near its low of $66.95. With a beta of 1.305, this downtrend is amplified by market volatility, and the -13.37 relative strength vs. the S&P 500 over the past month shows intense selling pressure.
- High Volatility & Market Underperformance: The stock's beta of 1.305 makes it 30% more volatile than the market, magnifying losses in downturns. It has significantly underperformed the S&P 500 over 1 year (-27.98 relative strength), indicating a loss of investor confidence and sector rotation away from the name.
GEHC Technical Analysis
The stock is in a pronounced downtrend, having declined 13.71% over the past three months and 11.91% over six months, culminating in a current price of $68.83, which sits at just 23.3% of its 52-week range ($66.95 to $89.77), indicating it is trading near its yearly lows and signaling potential oversold conditions or fundamental deterioration. Recent momentum is severely negative, with the stock down 4.67% over the past month, a trend that diverges from the modest 2.61% gain over the past year and highlights accelerating selling pressure, further evidenced by a significant -13.37 relative strength versus the S&P 500 over the same period. Key technical support is clearly defined at the 52-week low of $66.95, with resistance far above at $89.77; a breakdown below support could trigger further declines, while the stock's beta of 1.305 indicates it is approximately 30% more volatile than the broader market, which amplifies risk during this downtrend.
Beta
1.30
1.30x market volatility
Max Drawdown
-32.5%
Largest decline past year
52-Week Range
$59-$90
Price range past year
Annual Return
-12.6%
Cumulative gain past year
| Period | GEHC Return | S&P 500 |
|---|---|---|
| 1m | -13.5% | +12.6% |
| 3m | -24.5% | +2.5% |
| 6m | -20.6% | +4.3% |
| 1y | -12.6% | +28.4% |
| ytd | -28.2% | +4.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
GEHC Fundamental Analysis
Revenue growth has turned negative, with the most recent quarterly revenue of $4.674 billion representing a -12.13% year-over-year decline, and a sequential drop from $5.143 billion in Q3 2025, indicating a decelerating and contracting top-line trajectory that pressures the investment case. Profitability remains intact but is under pressure, with Q4 2025 net income of $184 million and a gross margin of 54.3%, yet net income has fallen sharply from $720 million in the year-ago quarter, and the trailing twelve-month net margin stands at 10.1%, reflecting margin compression from prior periods. The balance sheet shows moderate leverage with a debt-to-equity ratio of 0.96, and the company generates substantial cash, with free cash flow over the trailing twelve months of $1.506 billion, providing a strong liquidity position with a current ratio of 1.18 to fund operations and navigate the current cyclical downturn.
Quarterly Revenue
$4.7B
2025-12
Revenue YoY Growth
-0.12%
YoY Comparison
Gross Margin
+0.54%
Latest Quarter
Free Cash Flow
$1.5B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is GEHC Overvalued?
Given the company's positive net income, the primary valuation metric selected is the Price-to-Earnings (P/E) ratio. The trailing P/E stands at 17.97x, while the forward P/E is notably lower at 12.38x, indicating the market expects a significant earnings recovery in the coming year. Compared to sector averages, the stock's trailing P/E of 17.97x and Price-to-Sales (P/S) ratio of 1.82x appear reasonable for a healthcare technology leader, though a direct industry average is not provided in the data for a quantified premium/discount analysis. Historically, the current trailing P/E of 17.97x is below the stock's own historical range seen in recent quarters, which has included figures above 50x (Q4 2025) and as low as 12.4x (Q4 2024), suggesting the valuation is not at extended highs and may reflect the recent earnings pressure.
PE
18.0x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 12x~51x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
11.3x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks center on the sharp deterioration in core metrics. Revenue contracted -12.13% YoY in the latest quarter, and net income fell 74% from the year-ago period to $184M, indicating significant earnings volatility. While the balance sheet shows moderate leverage (Debt/Equity of 0.96) and strong liquidity (Current Ratio 1.18), the company is dependent on a recovery in equipment demand to justify its valuation. The high short ratio of 3.2 reflects market skepticism about a near-term turnaround.
Market & Competitive Risks are elevated due to valuation compression and sector headwinds. The stock's high beta (1.305) makes it sensitive to broader market pullbacks, which is concerning given its technical breakdown. Competitive disruption is a constant threat in medtech, and recent news of RadNet's AI acquisition highlights the industry's shift towards advanced diagnostics, potentially pressuring GEHC's legacy imaging dominance. Trading near 52-week lows, the stock faces the risk of further de-rating if growth does not re-accelerate.
Worst-Case Scenario involves a failure to stabilize revenues in the next two quarters, leading to consecutive earnings misses and guidance cuts. This could trigger analyst downgrades, a loss of investor confidence in the post-spin-off story, and a re-test of the 52-week low of $66.95. A breakdown below this key technical support could see the stock fall to levels implied by a forward P/E of 10x or lower during a broader market sell-off. From the current price of $68.83, this scenario presents a realistic downside of approximately -20% to -30%, aligning with the stock's maximum drawdown of -28.75% observed in the data.
FAQ
The primary risk is continued fundamental deterioration, evidenced by the -12.13% YoY revenue drop and 74% plunge in quarterly net income. Competitive and technological disruption risk is high, as seen in rival RadNet's AI acquisitions. Macro/market risk is elevated due to the stock's high beta (1.305), which amplifies losses in a down market, and its significant underperformance versus the S&P 500. Finally, execution risk remains as GEHC operates as a standalone entity post-spin-off during a challenging demand environment.
The 12-month outlook presents three scenarios. The base case (55% probability) sees the stock trading sideways in the $75-$80 range as revenue stabilizes but doesn't grow. The bull case (25% probability) projects a rally to $85-$90 on a clear recovery trajectory. The bear case (20% probability) warns of a drop to $65-$70 if the downturn worsens. The base case is most likely, predicated on the assumption that the current quarter represents the trough of the cycle, but a sharp rebound is not imminent.
GEHC appears fairly valued to slightly undervalued based on forward earnings expectations, but this is contingent on a recovery. The trailing P/E of 17.97x reflects past earnings pressure, while the forward P/E of 12.38x implies the market expects significant profit recovery. Compared to its own historical P/E range (which has been above 50x), the current multiple is not extended. The valuation implies the market is paying a fair price for a company in a downturn, with a discount applied for the uncertainty surrounding the timing and strength of the rebound.
GEHC presents a high-risk, potentially high-reward opportunity at current levels. For investors with a long-term horizon and high risk tolerance, the depressed price and reasonable forward P/E of 12.38x could be attractive if a cyclical recovery materializes in 2026. However, it is not a good buy for risk-averse or short-term investors, given the severe -12.13% revenue decline, negative technical momentum, and 30% higher volatility than the market (beta 1.305). The decision hinges entirely on one's conviction in a near-term operational turnaround.
GEHC is unsuitable for short-term trading due to its high volatility, negative momentum, and lack of near-term positive catalysts. It is better suited for long-term investors with a minimum 2-3 year horizon who believe in the durability of its medical technology franchise and its ability to recover from the current cyclical slump. The minimal dividend yield (0.17%) means the investment thesis is purely based on capital appreciation from a turnaround, which requires patience. The high beta also means it should only constitute a modest portion of a diversified portfolio.